GlassScriptPhysician profile
Carol E Ripple
NPI 1902100258
$2,449.81
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $639 · 2022: $610 · 2023: $969 · 2024: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.50 | 2021-2024 | |
| Ge Healthcare | $381.25 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $204.90 | 2023-2024 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $141.28 | 2021 | |
| Biogen, INC. | $121.30 | 2021-2023 | Vumerity, Tysabri |
| Bayer Healthcare Pharmaceuticals INC. | $120.77 | 2024 | |
| Idorsia Pharmaceuticals US INC | $115.39 | 2023 | Quviviq |
| Genzyme Corporation | $109.04 | 2021 | |
| Novartis Pharmaceuticals Corporation | $107.21 | 2022-2023 | |
| Allergan, INC. | $91.06 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $79.09 | 2023 | Amvuttra |
| Argenx US, INC. | $78.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.79 | 2022 | |
| Gilead Sciences, INC. | $49.50 | 2021 | |
| Eisai INC. | $45.73 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $45.34 | 2022-2023 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $43.16 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $26.58 | 2022 | |
| Amgen INC. | $24.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.51 | 2023 | Rexulti |
| Jazz Pharmaceuticals INC. | $23.57 | 2022 | |
| Sk Life Science, INC. | $23.43 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.63 | 2022 | |
| Acadia Pharmaceuticals INC | $22.20 | 2023 | Nuplazid |
| Corium, LLC | $21.11 | 2023 | Adlarity |
| Xeris Pharmaceuticals, INC. | $20.34 | 2022 | |
| Ucb, INC. | $19.80 | 2023 | |
| Pfizer INC. | $17.36 | 2023 | |
| Celgene Corporation | $12.73 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Ripple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.